HealthTrust's 340B Summit Tackles Policy Uncertainty and Compliance Pressures
Event summary
- HealthTrust hosted its third annual 340B Summit in Denver on July 22-23, 2026.
- The event focused on navigating policy uncertainty, operational pressures, and new compliance demands in the 340B Drug Pricing Program.
- Key topics included proposed changes to the 340B rebate-based purchasing model, contract pharmacy restrictions, and expanding manufacturer data reporting requirements.
- The summit featured experts from McKesson, Inmar Intelligence, SpendMend, K&L Gates LLP, and other industry stakeholders.
The big picture
HealthTrust's summit underscores the systemic changes facing the 340B Drug Pricing Program, as healthcare organizations grapple with policy uncertainty and operational pressures. The event highlights the need for strategic navigation of compliance demands and evolving industry dynamics, reflecting broader trends in pharmaceutical pricing and regulatory scrutiny.
What we're watching
- Regulatory Headwinds
- How proposed changes to the 340B rebate-based purchasing model will affect drug pricing and program effectiveness.
- Operational Pressures
- Whether healthcare organizations can sustain compliance with growing contract pharmacy networks and heightened audit focus.
- Policy Uncertainty
- The pace at which ongoing legal challenges and debates around 340B reform will impact program stability.
Related topics